ImmunoPrecise Antibodies (ImmunoPrecise Antibodies) Debt-to-Asset : 0.18 (As of Jan. 2024)

ImmunoPrecise Antibodies Debt-to-Asset Chart

ImmunoPrecise Antibodies Annual Data
	Trend	Dec13	Dec14	Dec15	Apr17	Apr18	Apr19	Apr20	Apr21	Apr22	Apr23
Debt-to-Asset		Get a 7-Day Free Trial					0.10	0.17	0.05	0.03	0.09

ImmunoPrecise Antibodies Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Debt-to-Asset	Get a 7-Day Free Trial															0.09	0.09	0.13	0.13	0.18

Competitive Comparison of ImmunoPrecise Antibodies's Debt-to-Asset

For the Biotechnology subindustry, ImmunoPrecise Antibodies's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImmunoPrecise Antibodies's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmunoPrecise Antibodies's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where ImmunoPrecise Antibodies's Debt-to-Asset falls into.

ImmunoPrecise Antibodies Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

ImmunoPrecise Antibodies's Debt-to-Asset for the fiscal year that ended in Apr. 2023 is calculated as

ImmunoPrecise Antibodies's Debt-to-Asset for the quarter that ended in Jan. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmunoPrecise Antibodies  (NAS:IPA) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

ImmunoPrecise Antibodies Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of ImmunoPrecise Antibodies's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmunoPrecise Antibodies (ImmunoPrecise Antibodies) Business Description